糖尿病(Diabetes)是一类以高血糖为特征可影响全身多个脏器和系统的慢性疾病,不仅使患者心血管、肾脏病等发病风险升高,也与骨质疏松的发生发展密切相关。骨质疏松一旦发生不可逆转,最终甚至演变为骨折的结局,给患者治疗和康复造成很大困难,因此早期预防至关重要。若能采取有效预防方法,就能降低糖尿病骨质疏松的患病率,减少患者痛苦、提高生活质量。本文主要就现阶段糖尿病患者如何预防骨质疏松的研究进展予以总结。
Diabetes is a chronic disease characterized by hyperglycemia that affects multiple organs and systems throughout the body. It not only increases the risk of cardiovascular and renal diseases, but also is closely related to the occurrence and development of osteoporosis. Once osteoporosis occurs irreversibly, it may even evolve into fracture, which causes great difficulties for the treatment and rehabilitation of patients. Therefore, early prevention is crucial. If effective prevention methods can be adopted, the prevalence of diabetic osteoporosis can be reduced, the pain of patients can be reduced, and the quality of life can be improved. This article mainly summarizes the research progress of how to prevent osteoporosis in diabetic patients at present.
糖尿病,骨质疏松,预防方法, Diabetes Mellitus Osteoporosis The Prevention Methods摘要
Diabetes is a chronic disease characterized by hyperglycemia that affects multiple organs and systems throughout the body. It not only increases the risk of cardiovascular and renal diseases, but also is closely related to the occurrence and development of osteoporosis. Once osteoporosis occurs irreversibly, it may even evolve into fracture, which causes great difficulties for the treatment and rehabilitation of patients. Therefore, early prevention is crucial. If effective prevention methods can be adopted, the prevalence of diabetic osteoporosis can be reduced, the pain of patients can be reduced, and the quality of life can be improved. This article mainly summarizes the research progress of how to prevent osteoporosis in diabetic patients at present.
Keywords:Diabetes Mellitus, Osteoporosis, The Prevention Methods
牛婷玉,李小凤. 糖尿病患者如何预防骨质疏松的研究进展Research Progress on How to Prevent Osteoporosis in Diabetic Patients[J]. 临床医学进展, 2022, 12(02): 1178-1185. https://doi.org/10.12677/ACM.2022.122171
参考文献References熊雪松, 余显霞. 2型糖尿病与骨质疏松症相关性研究进展[J]. 中国骨质疏松杂志, 2017, 23(1): 130-135.Li, Y.Z., Teng, D., Shi, X.G., et al. (2020) Prevalence of Diabetes Recorded in Mainland China Using 2018 Diagnostic Criteria from the American Diabetes Association: National cross Sectional Study. British Medical Journal, 369, m997.
<br>https://doi.org/10.1136/bmj.m997Notarnicola, A., et al. (2016) Epidemiology of Diabetes Mellitus in the Fragility Fracture Population of a Region of Southern Italy. Journal of Biological Regulators and Homeostatic Agents, 30, 297-302.Junk, J.K., et al. (2012) Fracture Incidence and Risk of Osteoporosis in Female Type 2 Diabetic Patients in Korea. Diabetes & Metabolism Journal, 36, 144-150. <br>https://doi.org/10.4093/dmj.2012.36.2.144de Liefde, I.I., van der Klift, M., de Laet, C.E., van Daele, P.L., Hofman, A. and Pols, H.A. (2005) Bone Mineral Density and Fracture Risk in Type-2 Diabetes Mellitus: The Rotterdam Study. Osteoporosis International, 16, 1713-1720.
<br>https://doi.org/10.1007/s00198-005-1909-1Ottenbacher, K.J., Ostir, G.V., Peek, M.K., Goodwin, J.S. and Markides, K.S. (2002) Diabetes Mellitus as a Risk Factor for Hip Fracture in Mexican American Older Adults. The Journals of Gerontology Series A. Biological Sciences and Medical Sciences, 57, M648-M653.Strotmeyer, E.S., Cauley, J.A., Schwartz, A.V., et al. (2005) Nontraumatic Fracture Risk with Diabetes Mellitus and Impaired Fasting Glucose in Older White and Black Adults: The Health, Aging, and Body Composition Study. Archives of Internal Medicine, 165, 1612-1617. <br>https://doi.org/10.1001/archinte.165.14.1612中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版) [J]. 中华糖尿病杂志, 2021, 13(4): 315-409.Viscoli, C.M., Inzucchi, S.E., Young, L.H., et al. (2017) Pioglitazone and Risk for Bone Fracture. Safety Data from a Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism, 102, 914-922.Ye, Y.L., Zhao, C.H., Liang, J., et al. (2018) Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Bone Metabolism and Fracture Risk. Frontiers in Pharmacology, 9, Article No. 1517. <br>https://doi.org/10.3389/fphar.2018.01517Lecka-Czernik, B. (2017) Diabetes, Bone and Glucose-Lowering Agents: Basic Biology. Diabetologia, 60, 1163-1169.
<br>https://doi.org/10.1007/s00125-017-4269-4Mai, Q.G., Zhang, Z.M., Xu, S., et al. (2011) Metformin Stimulates Osteoprotegerin and Reduces RANKL Expression in Osteoblasts and Ovariectomized Rats. Journal of Cellular Biochemistry, 112, 2902-2909.
<br>https://doi.org/10.1002/jcb.23206Schurman, L., McCarthy, A.D., Sedlinsky, C., et al. (2008) Metformin Reverts Deleterious Effects of Advanced Glycation End-Products (AGEs) on Osteoblastic Cells. Experimental and Clinical Endocrinology and Diabetes, 116, 333-340.Starup-Linde, J., Gregersen, S., Frost, M., et al. (2017) Use of Glucose-Lowering Drugs and Risk of Fracture in Patients with Type 2 Diabetes. Bone, 95, 136-142.Monami, M., Cresci, B., Colombini, A., et al. (2008) Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients: A Case-Control Study. Diabetes Care, 31, 199-203. <br>https://doi.org/10.2337/dc07-1736Campbell, J.E. and Drucker, D.J. (2013) Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metabolism, 17, 819-837.Nuche-Berenguer, B., Moreno, P., Portal-Núñez, S., et al. (2010) Exendin-4 Exerts Osteogenic Actions in Insulin-Resistant and Type 2 Diabetic States. Regulatory Peptides, 159, 61-66.Nuche-Berenguer, B., Portal-Núñez, S., Moreno, P., et al. (2010) Presence of a Functional Receptor for GLP-1 in Osteoblastic Cells, Independent of the cAMP-Linked GLP-1 Receptor. Journal of Cellular Physiology, 225, 585-592.
<br>https://doi.org/10.1002/jcp.22243Ma, X., Meng, J.R., Jia, M., et al. (2013) Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Prevents Osteopenia by Promoting Bone Formation and Suppressing Bone Resorption in Aged Ovariectomized Rats. Journal of Bone and Mineral Research, 28, 1641-1652. <br>https://doi.org/10.1002/jbmr.1898Papazafiropoulou, A., Papanas, N., Pappas, S., et al. (2014) Role of Endogenous GLP-1 and Its Agonists in Osteopenia and Osteoporosis: But We Little Know Until Tried. Current Diabetes Reviews, 10, 43-47.
<br>https://doi.org/10.2174/1573399810666140217114848Bunck, M.C., Eliasson, B., Cornér, A., et al. (2011) Exenatide Treatment Did Not Affect Bone Mineral Density Despite Body Weight Reduction in Patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 13, 374-377.
<br>https://doi.org/10.1111/j.1463-1326.2010.01355.xMonami, M., Dicembrini, I., Antenore, A., et al. (2011) Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A Meta-Analysis of Randomized Clinical Trials. Diabetes Care, 34, 2474-2476. <br>https://doi.org/10.2337/dc11-1099Hegazy, S.K. (2015) Evaluation of the Anti-Osteoporotic Effects of Metformin and Sitagliptin in Postmenopausal Diabetic Women. Journal of Bone and Mineral Metabolism, 33, 207-212. <br>https://doi.org/10.1007/s00774-014-0581-yBunck, M.C., Poelma, M., Eekhoff, E.M., et al. (2012) Effects of Vildagliptin on Postprandial Markers of Bone Resorption and Calcium Homeostasis in Recently Diagnosed, Well-Controlled Type 2 Diabetes Patients. Journal of Diabetes, 4, 181-185. <br>https://doi.org/10.1111/j.1753-0407.2011.00168.xSbaraglini, M.L., Molinuevo, M.S., Sedlinsky, C., et al. (2014) Saxagliptin Affects Long-Bone Microarchitecture and Decreases the Osteogenic Potential of Bone Marrow Stromal Cells. European Journal of Pharmacology, 727, 8-14.
<br>https://doi.org/10.1016/j.ejphar.2014.01.028Ma, P., Gu, B., Ma, J., Lingling, E., Wu, X., Cao, J., et al. (2010) Glimepiride Induces Prolife Ration and Differentiation of Rat Osteoblasts via the PI3-Kinase/Akt Pathway. Metabolism, 59, 359-366.Fronczek-Sokół, J. and Pytlik, M. (2014) Effect of Glimepiride on the Skeletal System of Ovariectomized and Non-Ovariectomized Rats. Pharmacological Reports, 66, 412-417. <br>https://doi.org/10.1016/j.pharep.2013.12.013Ma, P., Xiong, W., Liu, H.C., Ma, J.L., Gu, B. and Wu, X. (2011) Extrapancreatic Roles of Glimepiride on Osteoblasts from Rat Manibular Bone in Vitro: Regulation of Cytodifferentiation through PI3-Kinases/Akt Signalling Pathway. Archives of Oral Biology, 56, 307-316. <br>https://doi.org/10.1016/j.archoralbio.2010.10.009Kanazawa, I., Yamaguchi, T., Yamamoto, M. and Sugimoto, T. (2010) Relationship between Treatments with Insulin and Oral Hypoglycemic Agents versus the Presence of Vertebral Fractures in Type 2 Diabetes Mellitus. Journal of Bone and Mineral Metabolism, 28, 554-560. <br>https://doi.org/10.1007/s00774-010-0160-9Adila, M., Ali Khana, R., Kalama, A., Venkatab, S.K., Kandhareb, A.D., Ghoshb, P. and Sharmaa, M. (2017) Effect of Anti-Diabetic Drugs on Bone Metabolism: Evidence from Preclinical and Clinical Studies. Pharmacological Reports, 69, 1328-1340. <br>https://doi.org/10.1016/j.pharep.2017.05.008Thomas, D., Ng, K. and Insulin Best, J. (1997) Bone: A Clinical and Scientific Review. Endocrinology and Metabolism, 4, 5-17.Cornish, J., Callon, K. and Reid, I. (1996) Insulin Increases Histomorphometric Indices of Bone Formation in Vivo. Calcified Tissue International, 59, 492-495.Pastor, M.C., Lopez-Ibarra, P., Escobar-Jimenez, F., Pardo, M.S. and Garcia-Cervigon, A. (2000) Intensive Insulin Therapy and Bone Mineral Density in Type 1 Diabetes Mellitus: A Prospective Study. Osteoporosis International, 11, 455-459. <br>https://doi.org/10.1007/s001980070114Dennison, E.M., Syddall, H.E., Aihie Sayer, A., Craighead, S., Phillips, D.I. and Cooper, C. (2004) Type 2 Diabetes Mellitus Is Associated with Increased Axial Bone Density in Men and Women from the Hertfordshire Cohort Study: Evidence for an Indirect Effect of Insulin Resistance. Diabetologia, 47, 1963-1968.
<br>https://doi.org/10.1007/s00125-004-1560-yMelton, L.J., Leibson, C.L., Achenbach, S.J., Therneau, T.M. and Khosla, S. (2008) Fracture Risk in Type 2 Diabetes: Update of a Population-Based Study. Journal of Bone and Mineral Research, 23, 1334-1342.
<br>https://doi.org/10.1359/jbmr.080323Vestergaard, P., Rejnmark, L. and Mosekilde, L. (2005) Relative Fracture Risk in Patients with Diabetes Mellitus, and the Impact of Insulin and Oral Antidiabetic Medication on Relative Fracture Risk. Diabetologia, 48, 1292-1299.
<br>https://doi.org/10.1007/s00125-005-1786-3Mieczkowska, A., Baslé, M.F., Chappard, D. and Mabilleau, G. (2012) Thiazolidinediones Induce Osteocyte Apoptosis by a G Protein-Coupled Receptor 40-Dependent Mechanism. Journal of Biological Chemistry, 287, 23517-23526.Mabilleau, G., Mieczkowska, A. and Edmonds, M. (2010) Thiazolidinediones Induce Osteocyte Apoptosis and Increase Sclerostin Expression. Diabetic Medicine, 27, 925-932. <br>https://doi.org/10.1111/j.1464-5491.2010.03048.xAyus, J.C., Negri, A.L., Kalantar-Zadeh, K. and Moritz, M.L. (2012) Is Chronic Hyponatremia a Novel Risk Factor for Hip Fracture in the Elderly? Nephrology Dialysis Transplantation, 27, 3725-3731. <br>https://doi.org/10.1093/ndt/gfs412vTaylor, S.I., Blau, J.E. and Rother, K.I. (2015) Possible Adverse Effects of SGLT2 Inhibitors on Bone. The Lancet Diabetes & Endocrinology, 3, 8-10. <br>https://doi.org/10.1016/S2213-8587(14)70227-XSchwartz, A.V. (2017) Efficacy of Osteoporosis Therapies in Diabetic Patients. Calcified Tissue International, 100, 165-173. <br>https://doi.org/10.1007/s00223-016-0177-8Schwartz, A.V., Pavo, I., Alam, J., Disch, D.P., Schuster, D., Harris, J.M. and Krege, J.H. (2016) Teriparatide in Patients with Osteoporosis and Type 2 Diabetes. Bone, 91, 152-158. <br>https://doi.org/10.1016/j.bone.2016.06.017Murray, T.M. (1988) The Importance of Calcium in Osteoporosis Prevention. Official Position of the Osteoporosis Society of Canada. Osteoporosis Society of Canada Bulletin for Physicians, 1, 2-6.Baeke, F., Gysemans, C., Korf, H., et al. (2010) Vitamin D Insufficiency: Implications for the Immune System. Pediatric Nephrology, 25, 1597-1606. <br>https://doi.org/10.1007/s00467-010-1452-y张永文. 糖尿病膳食指南八条建议[J]. 家庭医学(下), 2019(11): 26-27.Colberg, S.R., Sigal, R.J., Yardley, J.E., et al. (2016) Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care, 39, 2065-2079. <br>https://doi.org/10.2337/dc16-1728邹冬梅, 冯平. 运动疗法对2型糖尿病老年患者骨质疏松情况的预防效果[J]. 基础医学与调查报告, 2020, 7(28): 281-282.Qin, R., Chen, T., Lou, Q.Q., et al. (2013) Excess Risk of Mortality and Cardiovascular Events Associated with Smoking among Patients with Diabetes: Meta-Analysis of Observational Prospective Studies. International Journal of Cardiology, 167, 342-350.刘凤娟, 周慧敏, 徐绍娟. 吸烟对老年男性糖尿病患者骨密度的影响[J]. 中国骨质疏松杂志. 2012, 18(9): 808-810.张洪霞, 刘丽红, 龚雄辉. 吸烟对中年男性糖尿病患者骨含量影响的研究[J]. 现代中西医结合杂志, 2010, 19(4): 427-428.姚坤, 侯丽艳, 姜丽平, 刘晓芳, 张聪, 汪源. 糖尿病性骨质疏松常见危险因素Meta分析[J]. 中国保健营养, 2019, 29(16): 8-9.陈一萍, 李芳渊, 楼晓君, 陈锦平, 边平达. 老年男性吸烟与骨转换标志物、骨密度和骨质疏松性骨折风险的关系[J]. 全科医学临床与教育, 2021, 19(1): 15-17.中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017) [J]. 中华内分泌代谢杂志, 2017, 33(10): 890-913.